Reuters reports that Moderna (NASDAQ:MRNA) announced Monday it is lowering its 2025 sales forecast by $1 billion due to weak demand for its COVID-19 vaccines and a slower rollout of its new respiratory syncytial virus (RSV) shot.
The company now expects annual revenue between $1.5 billion and $2.5 billion, primarily in the latter half of the year. That's down from its earlier estimate of $2.5 billion to $3.5 billion and below the $2.95 billion analysts had expected, based on LSEG data.
CEO Stephane Bancel said Moderna plans to cut 2025 cash costs by $1 billion, with another $500 million in reductions targeted for 2026. The company anticipates finishing 2025 with about $6 billion in cash and investments.
Moderna is banking on new products to reignite growth. It has filed for FDA approval of a combination COVID-19 and flu vaccineand expects a decision by May on its next-generation COVID-19 vaccine.The company plans to release its fourth-quarter earnings on Feb. 14.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。